NCT06347653View on ClinicalTrials.gov

Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2030

Conditions
Nodal T-follicular Helper Cell Lymphoma
Interventions
DRUG

linperlisib combined with CHOP regimen

"Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles."

Trial Locations (1)

Unknown

RECRUITING

Bejing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER